SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
DUBLIN, Ireland and TREVOSE, Pa., Aug. 10, 2017 -- Strongbridge Biopharma plc (NASDAQ:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that management will present at the Canaccord Genuity 37th Annual Growth Conference, taking place August 9-10, 2017 at the InterContinental in Boston.
Matthew Pauls, president and chief executive officer of Strongbridge Biopharma, will provide a corporate overview on Thursday, August 10 at 3:00 p.m. ET. The presentation will be webcast live and archived on the “Events & Presentations” page in the Investor section of the Company’s website at www.strongbridgebio.com.
About Strongbridge Biopharma
Strongbridge Biopharma is a commercial-stage global biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's first commercial product is KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis. KEVEYIS has orphan drug exclusivity status in the U.S. through August 7, 2022. In addition to establishing this neuromuscular disease franchise, the Company has a clinical-stage pipeline of therapies for rare endocrine diseases. Strongbridge's lead compounds include RECORLEV™ (levoketoconazole), a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome, and veldoreotide, a next-generation somatostatin analog being investigated for the treatment of acromegaly, with potential additional applications in Cushing's syndrome and neuroendocrine tumors. Both RECORLEV and veldoreotide have received orphan designation from the U.S. Food and Drug Administration and the European Medicines Agency. For more information, visit www.strongbridgebio.com.
Contacts: Corporate and Media Relations Elixir Health Public Relations Lindsay Rocco +1 862-596-1304 [email protected] Investor Relations U.S.: The Trout Group Marcy Nanus +1 646-378-2927 [email protected] Europe: First House Mitra Hagen Negård +47 21 04 62 19 [email protected] USA 900 Northbrook Drive Suite 200 Trevose, PA 19053 Tel. +1 610-254-9200 Fax. +1 215-355-7389
